Chronic cortical myoclonus may be due to multiple aetiological factors enhancing the excitability of motor cortex. The possibility that an abnormal serotonin transmission is involved in the generation of epileptic seizures and myoclonus has been discussed for a long time. In particular, previous research has demonstrated a reduction of tryptophan and other serotonin metabolites in animal models and in patients with progressive myoclonus epilepsy. Alpha-lactoalbumin (ALAC) is a whey protein rich in tryptophan, naturally present in human milk, and showing the highest tryptophan/neutral amino acids (LNAAs) ratio among all food-derived proteins. We conducted a pragmatic, double-blind, placebo-controlled, cross-over trial, followed by an open-label extension, to evaluate the tolerability and the antimyoclonic efficacy of ALAC in patients with chronic cortical myoclonus of various aetiologies. ALAC was generally well tolerated but statistical analysis failed to identify any significant benefit on myoclonus in our series. However, our data showed that ALAC therapy was associated to a striking improvement of sleep quality and depressive symptoms in these patients.
|Translated title of the contribution||A pilot randomized, double-blind, placebo-controlled, cross-over trial of the whey protein alfa-lactoalbumin in chronic cortical myoclonus|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - May 2012|
ASJC Scopus subject areas
- Clinical Neurology